Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04449913 in MDS and CMML
NCT01842646Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glasdegib in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Moffitt Cancer Center. Started Aug 2013; status: completed.
02
Drugs
glasdegib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01842646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842646.